# SSGJ-705

Source: https://onco.cc/drugs/ssgj-705/  
OnCo record `ssgj-705` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

SSGJ-705 is an experimental monoclonal antibody from Shenyang Sunshine Pharmaceutical in phase 2 trials, aimed at PD-1 and HER2.

## Summary

SSGJ-705 is a monoclonal antibody developed by Shenyang Sunshine Pharmaceutical. Its targets are PD-1 and HER2. ClinicalTrials.gov describes the intervention as: anti-PD-1 and anti-HER2 bispecifc antibody. It is the investigational product in 2 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials. The largest, NCT07022002, plans to enrol 340 participants with primary completion expected 2026-12-31. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-09-11
- Tags: pipeline; ctgov-ingest
- Modality: monoclonal antibody
- Mechanism: Monoclonal antibody directed at PD-1 and HER2, as stated in the ClinicalTrials.gov intervention record; the detailed mechanism is not stated.

## Sources

- ClinicalTrials.gov: trials of SSGJ-705: https://clinicaltrials.gov/search?intr=SSGJ-705

## Connected records

- targets: [HER2](https://onco.cc/targets/her2/), [PD-1](https://onco.cc/targets/pd1/)
- companies: [3SBio](https://onco.cc/companies/3sbio/)
- trials: [SSGJ-705 Monotherapy and Combination Therapy in Advanced HER2-Expressing Solid Tumors](https://onco.cc/trials/nct07022002/), [SSGJ-705 Plus SSGJ-612 ± Chemotherapy in Advanced HER2-Expressing Solid Tumors](https://onco.cc/trials/nct07646626/)

---
JSON: https://onco.cc/api/v1/entities/ssgj-705.json